|
||
Diabecontrol Pregnancy |
||
Diabecontrol crosses the placenta.
Severe hypoglycemia lasting 4 to 10 days has been noted in infants born to mothers taking a sulfonylurea (including Diabecontrol) at the time of delivery; additional adverse events have also been reported and may be influenced by maternal glycemic control (Jackson 1962; Kemball 1970; Uhrig 1983; Zucker 1968). The manufacturer recommends if Diabecontrol is used during pregnancy, it should be discontinued at least 1 month before the expected delivery date.
Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major birth defects, stillbirth, and macrosomia (ACOG 201 2018). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2020; Blumer 2013).
Agents other than Diabecontrol are currently recommended to treat diabetes mellitus in pregnancy (ADA 2020).
Use is not recommended Excreted into human milk: Yes
According to the manufacturer, an analysis of a composite of 2 samples of human breast milk obtained from 1 patient 5 hours after ingestion of a dose if 500 mg yielded a concentration of 5 mg/mL. Some experts feel this amount of drug in the breast milk is unlikely to affect a breastfed infant; however, shorter acting drugs are preferred to avoid drug accumulation. If a mother does breastfeed while on this drug, their breastfed infant's blood glucose should be monitored.
See references
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|